Meeting
2020 Gastrointestinal Cancers Symposium
Clinical utility of the systemic inflammatory response (SIR) in identifying high-risk stage II colon cancer.
Authors
Allan Matthew Golder
Academic Unit of Surgery, Glasgow, United Kingdom
Allan Matthew Golder , Donald C. McMillan , David Mansouri , Paul G. Horgan , Campbell SD Roxburgh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 220)
Abstract #
220
Poster Bd #
K20
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
The potential for combined measures of the systemic inflammatory response (SIR) in colon cancer: An analysis of 2,300 patients.
First Author: Allan Matthew Golder
Poster
2017 Gastrointestinal Cancers Symposium
Association of ongoing systemic inflammatory response (SIR) at diagnosis with lymph node retrieval and node positivity in patients undergoing surgery for colonic cancer.
First Author: Ross Dolan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The association between KRAS mutational status, clinicopathological factors including the preoperative systemic inflammatory response and outcomes in TNM stage I-III colon cancer.
First Author: Allan Matthew Golder
Poster
2020 ASCO Virtual Scientific Program
Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
First Author: Zehua Wu